Literature DB >> 25605369

CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease.

Adèle de Masson1, Jean-David Bouaziz1, Hélène Le Buanec2, Marie Robin3, Alix O'Meara3, Nathalie Parquet4, Michel Rybojad5, Estelle Hau2, Jean-Benoît Monfort2, Mylène Branchtein2, David Michonneau3, Valérie Dessirier2, Flore Sicre de Fontbrune3, Anne Bergeron6, Raphaël Itzykson7, Nathalie Dhédin7, Djaouida Bengoufa8, Régis Peffault de Latour9, Aliénor Xhaard3, Martine Bagot1, Armand Bensussan2, Gérard Socié9.   

Abstract

Interleukin 10 (IL-10)-producing B cells (regulatory B cells [Bregs]) regulate autoimmunity in mice and humans, and a regulatory role of IL-10-producing plasma cells has been described in mice. Dysfunction of B cells that maintain homeostasis may play a role in the pathogenesis of chronic graft-versus-host disease (cGVHD) after allogeneic stem cell transplantation. Here, we found a relation between decreased Breg frequencies and cGVHD severity. An impaired ability of B cells to produce IL-10, possibly linked to poor signal transducer and activator of transcription 3 and extracellular signal-regulated kinase phosphorylation, was found in patients with active cGVHD. IL-10 production was not confined to a single B-cell subset, but enriched in both the CD24(hi)CD27(+) and CD27(hi)CD38(hi) plasmablast B-cell compartments. In vitro plasmablast differentiation increased the frequency of IL-10-producing B cells. We confirmed that allogeneic transplant recipients had an impaired reconstitution of the memory B-cell pool. cGVHD patients had less CD24(hi)CD27(+) B cells and IL-10-producing CD24(hi)CD27(+) B cells. Patients with cGVHD had increased plasmablast frequencies but decreased IL-10-producing plasmablasts. These results suggest a role of CD24(hi)CD27(+) B-cell and plasmablast-derived IL-10 in the regulation of human cGVHD.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25605369     DOI: 10.1182/blood-2014-09-599159

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  64 in total

1.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Authors:  Anushruti Sarvaria; Rafet Basar; Rohtesh S Mehta; Hila Shaim; Muharrem Muftuoglu; Ahmad Khoder; Takuye Sekine; Elif Gokdemir; Kayo Kondo; David Marin; May Daher; Amin M Alousi; Abdullah Alsuliman; Enli Liu; Betul Oran; Amanda Olson; Roy B Jones; Uday Popat; Chitra Hosing; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-07-20       Impact factor: 22.113

2.  Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation.

Authors:  Yue Hu; Gan-Lin He; Xiang-Yu Zhao; Xiao-Su Zhao; Yu Wang; Lan-Ping Xu; Xiao-Hui Zhang; Xue-Zhong Yu; Kai-Yan Liu; Ying-Jun Chang; Xiao-Jun Huang
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

Review 3.  Aberrant B-cell homeostasis in chronic GVHD.

Authors:  Stefanie Sarantopoulos; Jerome Ritz
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

Review 4.  Innate B Cells: the Archetype of Protective Immune Cells.

Authors:  Alexis Grasseau; Marina Boudigou; Laëtitia Le Pottier; Nedra Chriti; Divi Cornec; Jacques-Olivier Pers; Yves Renaudineau; Sophie Hillion
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

5.  Suppression of autoimmunity by CD5(+) IL-10-producing B cells in lupus-prone mice.

Authors:  Y Baglaenko; K P Manion; N-H Chang; C Loh; G Lajoie; J E Wither
Journal:  Genes Immun       Date:  2015-05-14       Impact factor: 2.676

Review 6.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04

9.  An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

Authors:  Jonathan C Poe; Wei Jia; Hsuan Su; Sarah Anand; Jeremy J Rose; Prasanthi V Tata; Amy N Suthers; Corbin D Jones; Pei Fen Kuan; Benjamin G Vincent; Jonathan S Serody; Mitchell E Horwitz; Vincent T Ho; Steven Z Pavletic; Frances T Hakim; Kouros Owzar; Dadong Zhang; Bruce R Blazar; Christian W Siebel; Nelson J Chao; Ivan Maillard; Stefanie Sarantopoulos
Journal:  Blood       Date:  2017-08-29       Impact factor: 22.113

Review 10.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.